Slide 1: Corporate Presentation
Corporate Presentation A Breakthrough Neuropsychiatry Company November 13, 2025 NYSE American: CYBN Cboe CA: CYBN 1 1
Slide 2: Cautionary Statement
Cautionary Statement The information contained in this presentation has been prepared by Cybin Inc. and its affiliates (“Cybin” or the “Company”). The information contained in this presentation: (a) is provided as at the date hereof, is subject to change without notice, and is based on publicly avai
Slide 3: Leading the Development of Next-Generation, Differentiated Neuropsychiatry Therapeutics
Leading the Development of Next-Generation, Differentiated Neuropsychiatry Therapeutics1 Two proprietary clinical programs, CYB003 and CYB004, targeting major depressive disorder ("MDD") 1 and generalized anxiety disorder ("GAD") with positive Phase 2 safety and efficacy results Lead program CYB003
Slide 4: Leadership Team with Proven Record of Regulatory & Commercial Success
Leadership Team with Proven Record of Regulatory & Commercial Success Eric So Amir Inamdar MBBS, Alex Nivorozhkin, Ph.D. Aaron Bartlone Mirza I. Rahman, MD, Allison Interim Chief Executive DNB(Psych), FFPM Chief Scientific Officer Chief Operating Officer MPH, FAAFP, FACPM House-Gecewicz Officer Chie
Slide 5: Executing on Our Differentiated Pipeline to Drive Breakthroughs in Neuropsychiatry
Executing on Our Differentiated Pipeline to Drive Breakthroughs in Neuropsychiatry PROGRAM INDICATION PRECLINICAL PHASE 1 PHASE 2 PHASE 3 NEXT MILESTONES1,2,3 CYB003 Adjunctive Q4 2026: Phase 3 Deuterated Phase 3 study dosing underway treatment of Granted FDA Breakthrough Therapy Designation APPROAC
Slide 6: MDD and GAD: Leading Contributors to Mental Health Patient Burden
MDD and GAD: Leading Contributors to Mental Health Patient Burden Addressable Market Health Impact Need for Improved Treatments • Suicide risk is 20x higher for • 2/3rds of patients do not an individual with vs. experience relief with initial >300 million people without depression3 antidepressant tr
Slide 7: Portfolio strategy expands addressable market and commercial opportunity
Portfolio strategy expands addressable market and commercial opportunity5,6 Broaden addressable market & address comorbidities Leverage portfolio and drive commercial synergies Addressing overlapping needs in MDD and GAD CYB003 Build – Salesforce and distribution network – Reimbursement and contract
Slide 8: Strong IP Portfolio Supporting CYB003 and CYB004
Strong IP Portfolio Supporting CYB003 and CYB0041,2,3 U.S. Exclusivity Timeline 5 Yr NCE Exclusivity + NDA 30-Month Stay approval ~7.5 yrs 2041 P NCE exclusivity Granted Patent exclusivity Pending Protection ✓ Multilayered IP strategy ✓ Issued patents provide IP protection • Compositions and: until
Slide 9: Why Adjunctive Treatment Matters in MDD
Why Adjunctive Treatment Matters in MDD ] MDD in U.S.1,2 Benefits of adjunctive treatment: 21M adults ✓ Begin treatment immediately MDD ✓ Prevent withdrawal symptoms excluding contraindications ✓ Remove barriers to treatment transition 17M ✓ Build on benefits of background medications Moderate to se
Slide 10: Reducing Burden on Clinical Infrastructure
Reducing Burden on Clinical Infrastructure Interventional Psychiatry Clinics have been CYB003 offers the opportunity to significantly growing in the U.S. reduce treatment burden Approximately 8,000 existing Interventional Psychiatry Annual Treatment Burden – Number of Visits9 clinics with capacity 6
Slide 11: CYB003
CYB003 Deuterated Psilocin Program Adjunctive Treatment of MDD 11
Slide 12: CYB003 Program Overview
CYB003 Program Overview • U.S. FDA Breakthrough Therapy Designation for adjunctive treatment of MDD • Dosing underway in Phase 3 PARADIGM program • Next milestone: Initiation of enrollment in second pivotal study, EMBRACE, in Q4 20251,2,3 Positive 12-month Phase 2 Results in MDD (2 doses – 16 mg) Su
Slide 13: Large Improvement in Depression Symptoms After Single Dose of CYB003
Large Improvement in Depression Symptoms After Single Dose of CYB0031 MADRS change from baseline, mean (±SD) Improvement in symptoms Placebo Primary Effect p- (n=9) Dose1 Endpoint size value * 12 mg -14.11 2.31 0.0001 16 mg -12.99 2.54 0.0080 CYB003 16 mg (n=9) *Primary endpoint: difference in CYB00
Slide 14: CYB003: Sustained Improvements in Depression Symptoms at 12 Months
CYB003: Sustained Improvements in Depression Symptoms at 12 Months1 MADRS reduction from baseline Response and Remission 16 mg – 2 doses 16 mg – 2 Doses % Responders % Remitters 100 MADRS change from baseline, mean (±SD) 0 100 Improvement in symptoms -5 80 75 75 75 71 71 -10 D21 57 -15 60 -14.6 D42
Slide 15: Phase 3 PARADIGM Program Overview
Phase 3 PARADIGM Program Overview The pivotal program will consist of 2 studies plus an extension1,2,3: Study design • APPROACH: Two-arm study of two 16 mg doses of CYB003 vs. placebo aligned with FDA • EMBRACE: Three-arm study with two 16 mg doses, 8 mg doses, and a placebo arm guidance and two mee
Slide 16: PARADIGM: CYB003 Phase 3 Pivotal Program in MDD
PARADIGM: CYB003 Phase 3 Pivotal Program in MDD Day 1 Week 3 Week 6 Week 12 Dose 1 Dose 2 Primary Secondary endpoint1 endpoint2 APPROACH 16 mg 16 mg Responders CYB003-002 (n = 220) Relapse EXTEND Randomized 1:1 Placebo CYB003-004 Placebo 16 mg End of study 16 mg Long-term extension Relapse study wit
Slide 17: CYB004
CYB004 Deuterated Dimethyltryptamine (dDMT) Program in GAD 17
Slide 18: CYB004 Program Overview
CYB004 Program Overview Short-duration treatment with Demonstrated proof-of-concept Robust IP Protection convenient dosing in depression and anxiety for DMT/dDMT1 • Short-duration treatment • Strong datasets across 5 • >50 patents in support of clinical studies supporting CYB004 program • Intramuscu
Slide 19: Target Product Profile for dDMT Optimized with Data from 5 Clinical Studies
Target Product Profile for dDMT Optimized with Data from 5 Clinical Studies Completed Studies Key Findings Rapid and durable antidepressant and anxiolytic effect observed in DMT Phase 1/2a DMT study in moderate to ✓ 46% of MDD patients in remission at 3 months 1 severe MDD (no SSRIs) ✓ Among the pat
Slide 20: DMT Demonstrates Proof-of-Concept in Reducing Anxiety Symptoms
DMT Demonstrates Proof-of-Concept in Reducing Anxiety Symptoms 1 week 2 week 0 Change from baseline STAI-T score (mean) -1.9 -5 -3.4 ✓ Efficacy assessed as change from baseline in STAI-T scores1 -10 -11.0 ✓ Data from the MDD monotherapy -15 -13.5 (21.5 mg)2 and SSRI add on studies (27.5 mg)2 -20 -18
Slide 21: CYB004 in GAD: Phase 2 Proof-of-Concept Study
CYB004 in GAD: Phase 2 Proof-of-Concept Study Day 1 Week 3 Week 6 Week 12 Month 3–12 Screening Dose 1 Dose 2 Primary endpoint End of trial Optional follow-up Safety & Safety & Efficacy Efficacy Efficacy 24 Randomization Active CYB004 CYB004 IM active IM active on Day 1 Safety & Safety & Efficacy Eff
Slide 22: Value-Driving Milestones Across Development Pipeline
Value-Driving Milestones Across Development Pipeline1,2 2025 2026 ✓ Phase 2 CYB004 (IM) • Q1 2026: Topline data GAD study enrollment readout from Phase 2 complete study of CYB004 in GAD • Initiate enrollment in Phase 3 EMBRACE • Q4 2026: study of CYB003 in Q4 Topline efficacy 2025 data readout from
Slide 23: Thank You
Thank You NYSE American: CYBN | Cboe CA: CYBN Contact: ir@cybin.com 23
Slide 24: References
References SLIDE 6 SLIDE 7 1. World Health Organization. (2017). Depression and other common mental disorders: global 1) https://www.nimh.nih.gov/health/statistics/major-depression health estimates. World Health Organization. https://iris.who.int/handle/10665/254610. 2) Vasiliadis, H. M., Lesage, A.
Slide 25: Appendix
Appendix 25
Slide 26: CYB003: Phase 2a Trial Design in MDD
CYB003: Phase 2a Trial Design in MDD 1,2,3 Screening Treatment Period Optional Open Label Period Up to 4 weeks Day 1 Week 3 Week 6 4 months 12 months CYB003 CYB003 Placebo CYB003 Key Inclusion Criteria: Phase 1: Single ascending dose study (1-10 mg), n=12 ✓ Moderate to severe MDD (MADRS ≥ 21) Phase
Slide 27: Positive Phase 2 CYB003 Results in MDD
Positive Phase 2 CYB003 Results in MDD Rapid onset of effect Improvement in symptoms after single dose At 3 weeks: 12 mg better than placebo on MADRS by 14.1 points (p=0.0001), Cohen’s d=2.31 Large improvements in symptoms 16 mg better than placebo on MADRS by 13 points (p=0.008), Cohen’s d=2.54 Ave
Slide 28: Sustained Improvements in Depression Symptoms at 12 Months
Sustained Improvements in Depression Symptoms at 12 Months MADRS reduction from baseline MADRS reduction from baseline 2 x 12 mg doses 2 x 16 mg doses MADRS change from baseline, mean (±SD) 0 0 Improvement in symptoms -5 -5 -10 -10 D21 -15 -15 D21 D364 -14.6 D42 -17.7 -17.6 D270 -20 D270 -18.0 -20 D
Slide 29: Response and Remission at 12 Months: 12 mg & 16 mg
Response and Remission at 12 Months: 12 mg & 16 mg CYB003-001 CYB003-001b CYB003-001 CYB003-001b n=15 / n=8 n=10 / n=7 n=15 / n=8 n=10 / n=7 29
Slide 30: Favorable Safety Profile of CYB003
Favorable Safety Profile of CYB003 • No AEs were reported at the 12-month follow up. • No reports of suicidal ideation or behavior or any long-term adverse sequelae. In the short-term study: o No SAEs and no participant discontinued the study due to an AE. o Most common AEs were nausea, elevated blo